Product Development Strategy for Generic Drug

Accelerate your generic drug product’s journey to market with Freyr's strategic development and Regulatory Services. From initial concept to post-approval changes, we provide expert guidance to navigate complex regulatory landscapes and ensure commercial success.

Product Development Strategy for Generic Drug - Overview

In the realm of Product Development Strategy, drug development emerges as a time-consuming, costly, and complex process linked to a high degree of uncertainty regarding the market success or failure of the drug. As such, a clear and optimized Regulatory strategy is imperative. This strategy plays a crucial role in assessing future risks and formulating effective risk-mitigation plans to ensure the successful launch of the product.

Product-specific guidance for generic drug development provides a roadmap for each milestone during the drug development cycle for manufacturers to make sound investment decisions and prioritize and manage the project portfolio.

Freyr assists clients in their product development strategy and submissions with optimum utilization of the resources throughout the drug development process for the successful commercialization of drug products.

Product Development Strategy for Generic Drug - Expertise

  • Preparation of the Regulatory strategy for drug development and identification of the reference drug product.
  • Regulatory consultation for Quality by Design (QbD) protocols.
  • Finalization of the APIs, excipients, and packaging material specifications and tests.
  • Development of a product development strategy for bioequivalent and stability studies.
  • Strategic guidance in prototype formula clearance and final formula clearance w.r.t IIG, dose proportionality, size, and shape.
  • Regulatory consultation for HA communication and query handling.
  • Strategic consulting and Regulatory support for the preparation and submission of ANDAs and DMF.
  • Strategic support for the implementation of post-approval changes.
  • Competitors landscape evaluation and preparation of the right Regulatory strategies that suit product registrations.
  • Identify the right approach for each case/clinical program/marketing authorization strategy.
  • Orphan drug applications (ODD).
  • Product evaluation for suitability under the expedited programs and Regulatory support for the submission of expedited program requests.
  • Consultation on QbD protocols and reports.
  • Evaluation of the excipients against the IIG database.
  • Consultation on the protocols/reports for process validation, method validations, specifications, test methods, exhibit batch protocols, pilot-scale batches, commercial batch protocols, etc.
  • Consultation on defining the tests/risk assessments for genotoxic, elemental, and nitrosamine impurities.
  • Consultation on stability study requirements, considering bracketing and matrix concepts.
  • Consultation on the Reference Listed Drug (RLD) selection.
  • Consultation on the selection of dissolution parameters multimedia.
  • Consultation on responding to HA queries.
Product Development Strategy for Generic Drug

Celebrating Customers Success

 

Medicinal Products

Regulatory Affairs

India

Thank you for the timely support over the weekend, which allowed us to resubmit quickly after being notified. This continuously demonstrates Freyr's commitment towards our company’s milestones.

Director - Global Regulatory Affairs – Operations

India-based, Global Top Generic Pharma Company

 

Medicinal Products

Publishing

UK

I am sure you have heard by now that we have received our first-ever approval from the FDA for our Brands division. This is a major milestone for us as well as for my team here in Reg Ops. I would be remiss if I didn’t point out that we would not have been able to do this without the help of your dedicated team. From the original filing, then the following year of responses, all helped get us to final approval.

Thank you Freyr team for a job well done!

Sr. Director, Head of Regulatory Operations

Ireland-based, Global Specialty Pharmaceutical Company

 

Medicinal Products

Regulatory Affairs

USA

Please relate to the team the excellent job they have done on the IND reactivation. Specifically, the high-quality module 3, written by Freyr. It was very comprehensive, very few revisions were required, and we had no questions from Health Canada or FDA. No CMC questions: that was a first for me. So very responsive to my many requests, which I am sure can be frustrating but always helpful while producing excellent work.

Thank you for always being available and responding quickly and comprehensively to all my requests.

What a great team you have, Freyr.

Lynne McGrath

Regulatory Consultant

 

Medicinal Products

Regulatory Affairs

USA

Congratulations!!! ​

Thanks for your great support for a successful ANDA filing, especially to the publishing team. Heartfully appreciate their last hours of hard work.

Assistant Manager​

US-based, Leading, Complex Generic Pharmaceutical Products Company​

 

Medicinal Products

Regulatory Affairs

USA

Thank you all for the great support!​

CEO

US-based, Leading Innovative Pharmaceuticals Company​

 

Medicinal Products

Regulatory Affairs

USA

The ANDA receipt has been received! Thank you very much for your hard work, patience, and support for our work over the last couple of months. We are delighted that we were able to meet the timeline and hit an important corporate goal of our young company. ​

Thank you again, and we look forward to working with your team on the next project!

Senior Director of Business and Product Development​

US-based, Leading Innovator Pharmaceuticals Company​